{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:15:34Z","timestamp":1791486934099,"version":"4.3.4"},"reference-count":67,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypophosphataemia is an increasingly recognized side\u2010effect of ferric carboxymaltose (FCM) and possibly iron isomaltoside\/ferric derisomaltose (IIM), which are used to treat iron deficiency. The aim of this study was to determine frequency, severity, duration and risk factors of incident hypophosphataemia after treatment with FCM and IIM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic literature search for articles indexed in EMBASE, PubMed and Web of Science in years 2005\u20132020 was carried out using the search terms \u2018ferric carboxymaltose\u2019 OR \u2018iron isomaltoside\u2019. Prospective clinical trials reporting outcomes on hypophosphataemia rate, mean nadir serum phosphate and\/or change in mean serum phosphate from baseline were selected. Hypophosphataemia rate and severity were compared for studies on IIM\n                      <jats:italic>vs<\/jats:italic>\n                      . FCM after stratification for chronic kidney disease. Meta\u2010regression analysis was used to investigate risk factors for hypophosphataemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Across the 42 clinical trials included in the meta\u2010analysis, FCM induced a significantly higher incidence of hypophosphataemia than IIM (47%, 95% CI 36\u201358%\n                      <jats:italic>vs<\/jats:italic>\n                      . 4%, 95% CI 2\u20135%), and significantly greater mean decreases in serum phosphate (0.40\n                      <jats:italic>vs<\/jats:italic>\n                      . 0.06 mmol\/L). Hypophosphataemia persisted at the end of the study periods (maximum 3 months) in up to 45% of patients treated with FCM. Meta\u2010regression analysis identified low baseline serum ferritin and transferrin saturation, and normal kidney function as significant predictors of hypophosphataemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FCM is associated with a high risk of hypophosphataemia, which does not resolve for at least 3 months in a large proportion of affected patients. More severe iron deficiency and normal kidney function are risk factors for hypophosphataemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.14643","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T21:37:18Z","timestamp":1605303438000},"page":"2256-2273","source":"Crossref","is-referenced-by-count":124,"title":["Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8690-2774","authenticated-orcid":false,"given":"Benedikt","family":"Schaefer","sequence":"first","affiliation":[{"name":"Department of Medicine I, Gastroenterology, Hepatology and Endocrinology Medical University of Innsbruck  Innsbruck Austria"},{"name":"Christian Doppler Laboratory of Iron and Phosphate Biology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Tobiasch","sequence":"additional","affiliation":[{"name":"Department of Medicine University Teaching Hospital of Hall in Tirol  Hall Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Viveiros","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Gastroenterology, Hepatology and Endocrinology Medical University of Innsbruck  Innsbruck Austria"},{"name":"Christian Doppler Laboratory of Iron and Phosphate Biology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Gastroenterology, Hepatology and Endocrinology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"IBD Pharmacogenetics University of Exeter  Exeter UK"},{"name":"Gastrointestinal Unit Western General Hospital  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, and Duke Clinical Research Institute Duke University School of Medicine  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-422X","authenticated-orcid":false,"given":"Heinz","family":"Zoller","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Gastroenterology, Hepatology and Endocrinology Medical University of Innsbruck  Innsbruck Austria"},{"name":"Christian Doppler Laboratory of Iron and Phosphate Biology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12289"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.1498914"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S89704"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2326-11-4"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.04.013"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0332-3"},{"issue":"6","key":"e_1_2_10_8_1","first-page":"399","article-title":"The efficacy and safety of current intravenous iron preparations for the management of iron\u2010deficiency anaemia: a review","volume":"60","author":"Qunibi WY","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000275286.03283.18"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.335"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167146"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-281"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-167"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0391-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100862"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.45.431"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2008.008151"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2396"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14231"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14747"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2011.06.009"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25564"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2009.00409.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/172104"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv096"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa011"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN108941"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1729"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2016-0050"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs528"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2016.1196496"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15386"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.12.010"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.03.025"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094217"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14521"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12477"},{"issue":"9","key":"e_1_2_10_43_1","first-page":"1628","article-title":"A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy","volume":"33","author":"Huang LL","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/169107"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2400-z"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2501-8"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2529-9"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12278"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv293"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft424"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2015.09.007"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft251"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq613"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.07.046"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9642027"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.448"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2728-3"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02327.x"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124486"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.13.15"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4901-52"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc9215"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0087-2"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9533-z"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0189-5"},{"key":"e_1_2_10_67_1","unstructured":"European Medicines Agency.Amendments to the product information of the nationally authorised medicinal product.https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/iron-parenteral-preparations-except-iron-dextran-cmdh-scientific-conclusions-grounds-variation\/00010236\/202001_en.pdf. Accessed Oct 2020."},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez627"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T13:19:03Z","timestamp":1693574343000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1111\/bcp.14643"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14643","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]}}}